Abstract
Objectives To forecast the true growth of COVID-19 cases in Singapore after accounting for asymptomatic infections, we study and make modifications to the SEIR (Susceptible-Exposed-Infected-Recovered) epidemiological model by incorporating hospitalization dynamics and the presence of asymptomatic cases. We then compare the simulation results of our three epidemiological models of interest against the daily reported COVID-19 case counts across the time period from 23rd January to 6th April 2020. Finally, we compare and evaluate on the performance and accuracy of the aforementioned models’ simulations.
Methods Three epidemiological models are used to forecast the true growth of COVID-19 case counts by accounting for asymptomatic infections in Singapore. They are the exponential model, SEIR model with hospitalization dynamics (SEIHRD), and the SEIHRD model with inclusion of asymptomatic cases (SEAIHRD).
Results Simulation results of all three models reflect underestimation of COVID-19 cases in Singapore during the early stages of the pandemic. At a 40% asymptomatic proportion, we report basic reproduction number R0 = 3.28 and 3.74 under the SEIHRD and SEAIHRD models respectively. At a 60% asymptomatic proportion, we report R0 = 3.48 and 3.96 under the SEIHRD and SEAIHRD models respectively.
Conclusions Based on the results of different simulation scenarios, we are highly confident that the number of COVID-19 cases in Singapore was underestimated during the early stages of the pandemic. This is supported by the exponential increase of COVID-19 cases in Singapore as the pandemic developed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
e-mail: palash.ghosh{at}iitg.ac.in
e-mail: bibhas.chakraborty{at}duke-nus.edu.sg
Data Availability
The data that support the findings of this study are openly available in Singapore: Coronavirus Pandemic Country Profile at https://ourworldindata.org/coronavirus/country/singapore.
